Irritable Bowel Syndrome and Osteopathic Manipulative Therapy (IBSOMT)

Description

The Irritable Bowel Syndrome (IBS) is defined by the association between abdominal pain, bowel dysfunction for longer or shorter periods of time, but in any case, recurring. The absence of well-defined pathophysiological marker, requires a clinical definition. The most used are the Rome criteria III whose version was published in 2006, Version IV is under development.

coordinator's team demonstrated in a randomized, placebo-controlled, 31 patients with refractory IBS, visceral osteopathy that is associated with a significant improvement in diarrhea, abdominal distension and abdominal pain without change constipation. This improvement was associated with a decrease in rectal sensitivity without changes of depression, time of total or segmental colonic transit. This effect persisted one year after the end of this essay.

Primary objective To evaluate the efficacy of osteopathic manipulative treatment on IBS symptoms in IBS adult patients over a 3-sessions period according to our preliminary study (73).

Secondary objectives To evaluate and to compare the results of two therapeutic modalities : osteopathic manipulative treatment and placebo manipulative treatment on

• Subjective clinical criteria: Constipation, Diarrhea, abdominal pain, bloating, topology of abdominal pain.
• Improvement of quality of life
• Decrease of depression and anxiety
• Changes in the medication after treatment
• Search for a possible practitioner effect.

Experimental design:

Double-blind, randomized, placebo-controlled study, parallel group multicenter French study of 3 OMT sessions followed by an 18-week follow-up period.

Patients will be randomized in a 1:1 ratio to receive osteopathic manipulative treatment or placebo manipulative treatment every 2 weeks with stratification according to the IBS phenotype (IBS-C, IBS-D, IBS-M, IBS-U).

Description of research methodology

Design Double blind randomized clinical trial with a distribution of subjects in groups at a ratio (1:1) It is a double blind, multicenter, comparative, prospective, two-arms randomized study.

• One group of patients will benefit from OMT for the treatment of irritable bowel syndrome.
• One group of patients will receive a placebo manipulation therapy for the treatment of irritable bowel syndrome Schedule

The schedule will include 7 visits:

• Four medical visits: V0 (inclusion), V4 (at week 8), V5 at week 12 and V6 at week 24 respectively;
• Three osteopathic visits (V1, V2, V3) that correspond to the visceral or placebo manipulative treatment at week 2, 4, and 6, respectively.
• If patients, are not able to immediately participate to the study a screening visit (VS) could be added in order to separate the decision of participation and the beginning of the study.

Efficacy assessment The main criteria for treatment efficacy are the value of the IBS severity score. The IBS severity score was established from the self-administered questionnaire developed and validated by Francis. The French version was validated by the MAPI Research Institute. This questionnaire includes two items concerning abdominal pain and abdominal bloating (yes/no) and four visual analog scales (1-100) to assess the severity of abdominal pain, bloating, relief after stool, and impact of symptoms on quality of life. The number of days the patient suffered during the last 10 days was also recorded. The responses were used to calculate a quantitative severity score from 0 to 500 used to make a qualitative classification: severity score 75-175 = mild, 175-300 = moderate, > 300 = severe.

This questionnaire will be registered 7 times, at inclusion (V0), during each osteopathic visit (V1, V2, V3) and each medical visit (V4, V5, V6):

• Before treatment at (V0),
• During visceral manipulative treatment (V1, V2, V3)
• During the follow-up period, after visceral manipulative treatment (osteopathic or placebo),
• At 8 weeks (V4) after inclusion,
• At 12 weeks (V5) after inclusion and
• At 24 weeks (V6) at the end of follow up visit In each center, local osteopaths will be learned to provide the same placebo or osteopathic manipulation

Number of subjects chosen: 210 patients Sample Size Considering that the minimal clinical difference on the primary outcome measure that would lead clinicians to change the treatment is 50 points the IBS Symptom Severity Score, and that the standard deviation of this variable is 105 points, the sample size required to detect a difference at 90% power and 5% two-sided significance level is 94 patients/group .

To allow for loss to follow up around 10%, the total sample size of the trial would will be N=210 patients.

Number of centres 7 centres are included. Research period

• Inclusion period : 60 months
• Treatment period : 6 weeks
• Follow up period : 18 weeks Total research period: 66 months.

Statistical analysis Descriptive Statistics

All study variables will be presented by treatment and overall, by using the appropriate descriptive statistics according to the variable nature, unless otherwise specified:

• Continuous variables: number of non-missing observations, mean, standard deviation, standard error of the mean, minimum, median, maximum.
• Categorical variables: number of non-missing observations and column percentages (N, %) in each category.

Primary efficacy endpoint Primary endpoint: Changes from baseline of IBSSS at V4, will be analyzed by mixed model of ANCOVA with patient as random factor. Baseline value of the score as well as variables a priori known to affect the score will be included in the model.

Secondary efficacy endpoints

• Secondary efficacy variables with binary outcome (i.e. responder status) will be analysed using a Chi-square or Fisher's exact test in a 2 x 2 contingency table to compare active treatment group with placebo. A two-sided overall significance level of 5 % will be used.
• Secondary efficacy variables with continuous variables (i.e. "change from baseline") will be evaluated through an analysis of covariance (ANCOVA) models with fixed effect terms for treatment group and the patient's corresponding baseline value of the parameter as a covariate. The rebound effect will be evaluated with pairwise t-test.
• Exploratory efficacy endpoints and safety endpoints will be analysed only by descriptive statistics.

For the efficacy endpoints, the following subgroup-analyses will be presented:

• Age (<65 years vs. 65 years).
• Baseline abdominal pain severity (pain intensity on the 11-point NRS) <5, 5 to <8, 8).
• Baseline IBS-SSS score (mild IBS: <175 score points, moderate IBS: 175 to <300 score points, severe IBS: 300 score points).
• BMI (<30 kg/m vs. BMI 30 kg/m).
• Osteopath effect: analysis of data according to the osteopath that practiced the manipulative treatment.
• Analysis according to the subtype of IBS (IBS with constipation, IBS with diarrhoea, Mixed IBS, Unspecified IBS).

Details